Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.4
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 23239825
Just S, et al. (2013) Differentiation of opioid drug effects by hierarchical multi-site phosphorylation. Mol Pharmacol 83, 633-9 23239825
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S363-p - MOR-1 (mouse)
Modsite: STIEQQNsARIRQNt SwissProt Entrez-Gene
Orthologous residues
MOR‑1 (human): S365‑p, MOR‑1 iso5 (human): S365‑p, MOR‑1 (mouse): S363‑p, MOR‑1 (rat): S363‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  'neuron, striatal'-brain, 293 (epithelial)
Cellular systems studied:  cell lines, primary cultured cells
Species studied:  human, rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
DAMGO increase
fentanyl increase
etonitazene increase
morphine no change compared to control

T370-p - MOR-1 (mouse)
Modsite: sARIRQNtREHPstA SwissProt Entrez-Gene
Orthologous residues
MOR‑1 (human): T372‑p, MOR‑1 iso5 (human): T372‑p, MOR‑1 (mouse): T370‑p, MOR‑1 (rat): T370‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  'neuron, striatal'-brain, 293 (epithelial)
Cellular systems studied:  cell lines, primary cultured cells
Species studied:  human, rat
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE GRK3 (mouse) siRNA inhibition of enzyme
KINASE GRK2 (mouse) siRNA inhibition of enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
DAMGO increase
fentanyl increase
etonitazene increase
morphine no change compared to control

S375-p - MOR-1 (mouse)
Modsite: QNtREHPstANtVDR SwissProt Entrez-Gene
Orthologous residues
MOR‑1 (human): S377‑p, MOR‑1 iso5 (human): S377‑p, MOR‑1 (mouse): S375‑p, MOR‑1 (rat): S375‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  'neuron, striatal'-brain, 293 (epithelial)
Cellular systems studied:  cell lines, primary cultured cells
Species studied:  human, rat
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE GRK3 (mouse) siRNA inhibition of enzyme
KINASE GRK2 (mouse) siRNA inhibition of enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
DAMGO increase
fentanyl increase
etonitazene increase
morphine increase
Downstream Regulation
Effect of modification (function):  phosphorylation, receptor internalization, induced

T376-p - MOR-1 (mouse)
Modsite: NtREHPstANtVDRT SwissProt Entrez-Gene
Orthologous residues
MOR‑1 (human): T378‑p, MOR‑1 iso5 (human): T378‑p, MOR‑1 (mouse): T376‑p, MOR‑1 (rat): T376‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  'neuron, striatal'-brain, 293 (epithelial)
Cellular systems studied:  cell lines, primary cultured cells
Species studied:  human, rat
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE GRK3 (mouse) siRNA inhibition of enzyme
KINASE GRK2 (mouse) siRNA inhibition of enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
DAMGO increase
fentanyl increase
etonitazene increase
morphine no change compared to control
Downstream Regulation
Effect of modification (function):  receptor internalization, induced

T379-p - MOR-1 (mouse)
Modsite: EHPstANtVDRTNHQ SwissProt Entrez-Gene
Orthologous residues
MOR‑1 (human): T381‑p, MOR‑1 iso5 (human): T381‑p, MOR‑1 (mouse): T379‑p, MOR‑1 (rat): T379‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  'neuron, striatal'-brain, 293 (epithelial)
Cellular systems studied:  cell lines, primary cultured cells
Species studied:  human, rat
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE GRK3 (mouse) siRNA inhibition of enzyme
KINASE GRK2 (mouse) siRNA inhibition of enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
DAMGO increase
fentanyl increase
etonitazene increase
morphine no change compared to control
Downstream Regulation
Effect of modification (function):  receptor internalization, induced